Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.

Here is some news of note for the week: Apotex is dangling a $10 million reward in its CEO’s murder.

The FDA continues to find issues with Dr. Reddy’s oncology formulation facility at Duvvada, one of three cited in a warning letter.

Astellas will invest $255 million in production and R&D as it pushes into gene and cell therapies for cancer and other diseases.

India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.

Merck's Gardasil generated $1 billion in Q3, prompting an analyst to wonder just how much the shot might be able to generate in the long run.

Aspen Pharmacare says it will invest nearly $235 million in a facility to manufacture sterile anesthetics.

EMA inspectors have uncovered big manufacturing and quality concerns at sterile injectables plant of Genfarma Laboratorio in Spain.